{
"info": {
"nct_id": "NCT01955473",
"official_title": "A Japanese Phase I Open-label Dose-escalation Trial of Sym004 Administered as Monotherapy in Japanese Subjects With Advanced Solid Tumors",
"inclusion_criteria": "* Japanese male or female subjects aged greater than or equal to 20 years at the time of informed consent signature\n* Histologically or cytologically confirmed cancer\n* Refractory or recurrent advanced late stage solid tumors without available therapeutic options which are likely to provide patient benefit (failure and/or intolerance to standard anti-cancer therapy)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Life expectancy of at least 3 months\n* Written informed consent given before any trial-related activities are carried out\n* Other protocol defined inclusion criteria could apply\nHealthy volunteers allowed\nMust have minimum age of 20 Years",
"exclusion_criteria": "* Subjects with symptomatic brain metastases\n* Subjects who received total resection or irradiation of the target lesion\n* Received any of the following medications within 4 weeks before the first administration of Sym004 at Week 1: cytotoxic or cytostatic anti-cancer therapy, antibody therapy, tyrosine kinase inhibitors, and any investigational agent\n* Received vaccine therapy as anticancer treatment within 12 weeks before the first administration of Sym004 at Week 1\n* Diarrhea of greater than Grade 1 according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 (v4.03)\n* Skin manifestation of greater than Grade 1 according to NCI-CTCAE (v4.03)\n* Magnesium of less than 0.9 milligram per deciliter (mg/dL)\n* Abnormal organ or bone marrow function as defined in the protocol\n* Received immunosuppressive agents (including systemic corticosteroids used at doses above 20 milligram per day (mg/day) of prednisolone or equivalent) within 4 weeks before the first administration of Sym004 at Week 1\n* Active severe infection, any other concurrent disease or medical conditions that are deemed to interfere with the conduct of the trial as judged by the Investigator\n* Known human immunodeficiency virus (HIV) positive, active Hepatitis B or C, or uncontrolled allergic conditions or allergy to Sym004 or its components\n* Clinically significant cardiac disease or concurrent, uncontrolled medical condition\n* Known previous Grade 3 to 4 infusion-related reactions, according to NCI-CTCAE (v4.03), with chimeric monoclonal antibodies\n* Other protocol defined exclusion criteria could apply",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "* Japanese male or female subjects aged greater than or equal to 20 years at the time of informed consent signature",
"criterions": [
{
"exact_snippets": "Japanese male or female subjects",
"criterion": "ethnicity",
"requirement": {
"requirement_type": "presence",
"expected_value": "Japanese"
}
},
{
"exact_snippets": "male or female subjects",
"criterion": "gender",
"requirement": {
"requirement_type": "presence",
"expected_value": [
"male",
"female"
]
}
},
{
"exact_snippets": "aged greater than or equal to 20 years",
"criterion": "age",
"requirement": {
"requirement_type": "age",
"expected_value": {
"operator": ">=",
"value": 20,
"unit": "years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Japanese male or female subjects",
"criterion": "ethnicity",
"requirement": {
"requirement_type": "presence",
"expected_value": "Japanese"
}
},
{
"exact_snippets": "male or female subjects",
"criterion": "gender",
"requirement": {
"requirement_type": "presence",
"expected_value": [
"male",
"female"
]
}
},
{
"exact_snippets": "aged greater than or equal to 20 years",
"criterion": "age",
"requirement": {
"requirement_type": "age",
"expected_value": {
"operator": ">=",
"value": 20,
"unit": "years"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Histologically or cytologically confirmed cancer",
"criterions": [
{
"exact_snippets": "Histologically or cytologically confirmed cancer",
"criterion": "cancer",
"requirement": {
"requirement_type": "confirmation method",
"expected_value": [
"histologically",
"cytologically"
]
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Histologically or cytologically confirmed cancer",
"criterion": "cancer",
"requirement": {
"requirement_type": "confirmation method",
"expected_value": [
"histologically",
"cytologically"
]
}
}
]
}
},
{
"identified_line": {
"line": "* Refractory or recurrent advanced late stage solid tumors without available therapeutic options which are likely to provide patient benefit (failure and/or intolerance to standard anti-cancer therapy)",
"criterions": [
{
"exact_snippets": "Refractory or recurrent advanced late stage solid tumors",
"criterion": "solid tumors",
"requirement": {
"requirement_type": "stage",
"expected_value": "advanced late stage"
}
},
{
"exact_snippets": "Refractory or recurrent advanced late stage solid tumors",
"criterion": "solid tumors",
"requirement": {
"requirement_type": "condition",
"expected_value": [
"refractory",
"recurrent"
]
}
},
{
"exact_snippets": "without available therapeutic options which are likely to provide patient benefit",
"criterion": "therapeutic options",
"requirement": {
"requirement_type": "availability",
"expected_value": false
}
},
{
"exact_snippets": "failure and/or intolerance to standard anti-cancer therapy",
"criterion": "standard anti-cancer therapy",
"requirement": {
"requirement_type": "response",
"expected_value": [
"failure",
"intolerance"
]
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Refractory or recurrent advanced late stage solid tumors",
"criterion": "solid tumors",
"requirement": {
"requirement_type": "stage",
"expected_value": "advanced late stage"
}
},
{
"exact_snippets": "Refractory or recurrent advanced late stage solid tumors",
"criterion": "solid tumors",
"requirement": {
"requirement_type": "condition",
"expected_value": [
"refractory",
"recurrent"
]
}
}
]
},
{
"exact_snippets": "without available therapeutic options which are likely to provide patient benefit",
"criterion": "therapeutic options",
"requirement": {
"requirement_type": "availability",
"expected_value": false
}
}
]
},
{
"exact_snippets": "failure and/or intolerance to standard anti-cancer therapy",
"criterion": "standard anti-cancer therapy",
"requirement": {
"requirement_type": "response",
"expected_value": [
"failure",
"intolerance"
]
}
}
]
}
},
{
"identified_line": {
"line": "* Life expectancy of at least 3 months",
"criterions": [
{
"exact_snippets": "Life expectancy of at least 3 months",
"criterion": "life expectancy",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "months"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Life expectancy of at least 3 months",
"criterion": "life expectancy",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "months"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Written informed consent given before any trial-related activities are carried out",
"criterions": [
{
"exact_snippets": "Written informed consent given",
"criterion": "informed consent",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Written informed consent given",
"criterion": "informed consent",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Other protocol defined inclusion criteria could apply",
"criterions": [
{
"exact_snippets": "Other protocol defined inclusion criteria",
"criterion": "protocol defined inclusion criteria",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Other protocol defined inclusion criteria",
"criterion": "protocol defined inclusion criteria",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 20 Years",
"criterions": [
{
"exact_snippets": "minimum age of 20 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 20,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 20 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 20,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "* Subjects with symptomatic brain metastases",
"criterions": [
{
"exact_snippets": "symptomatic brain metastases",
"criterion": "brain metastases",
"requirement": {
"requirement_type": "symptom presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "symptomatic brain metastases",
"criterion": "brain metastases",
"requirement": {
"requirement_type": "symptom presence",
"expected_value": true
}
}
}
},
{
"identified_line": {
"line": "* Subjects who received total resection or irradiation of the target lesion",
"criterions": [
{
"exact_snippets": "Subjects who received total resection",
"criterion": "target lesion resection",
"requirement": {
"requirement_type": "procedure",
"expected_value": "total resection"
}
},
{
"exact_snippets": "Subjects who received ... irradiation of the target lesion",
"criterion": "target lesion irradiation",
"requirement": {
"requirement_type": "procedure",
"expected_value": "irradiation"
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Subjects who received total resection",
"criterion": "target lesion resection",
"requirement": {
"requirement_type": "procedure",
"expected_value": "total resection"
}
},
{
"exact_snippets": "Subjects who received ... irradiation of the target lesion",
"criterion": "target lesion irradiation",
"requirement": {
"requirement_type": "procedure",
"expected_value": "irradiation"
}
}
]
}
},
{
"identified_line": {
"line": "* Received any of the following medications within 4 weeks before the first administration of Sym004 at Week 1: cytotoxic or cytostatic anti-cancer therapy, antibody therapy, tyrosine kinase inhibitors, and any investigational agent",
"criterions": [
{
"exact_snippets": "Received any of the following medications within 4 weeks before the first administration of Sym004 at Week 1: cytotoxic or cytostatic anti-cancer therapy",
"criterion": "cytotoxic or cytostatic anti-cancer therapy",
"requirement": {
"requirement_type": "time since last administration",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 4,
"unit": "weeks"
}
]
}
}
},
{
"exact_snippets": "Received any of the following medications within 4 weeks before the first administration of Sym004 at Week 1: ... antibody therapy",
"criterion": "antibody therapy",
"requirement": {
"requirement_type": "time since last administration",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 4,
"unit": "weeks"
}
]
}
}
},
{
"exact_snippets": "Received any of the following medications within 4 weeks before the first administration of Sym004 at Week 1: ... tyrosine kinase inhibitors",
"criterion": "tyrosine kinase inhibitors",
"requirement": {
"requirement_type": "time since last administration",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 4,
"unit": "weeks"
}
]
}
}
},
{
"exact_snippets": "Received any of the following medications within 4 weeks before the first administration of Sym004 at Week 1: ... any investigational agent",
"criterion": "investigational agent",
"requirement": {
"requirement_type": "time since last administration",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 4,
"unit": "weeks"
}
]
}
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Received any of the following medications within 4 weeks before the first administration of Sym004 at Week 1: cytotoxic or cytostatic anti-cancer therapy",
"criterion": "cytotoxic or cytostatic anti-cancer therapy",
"requirement": {
"requirement_type": "time since last administration",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 4,
"unit": "weeks"
}
]
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "Received any of the following medications within 4 weeks before the first administration of Sym004 at Week 1: ... antibody therapy",
"criterion": "antibody therapy",
"requirement": {
"requirement_type": "time since last administration",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 4,
"unit": "weeks"
}
]
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "Received any of the following medications within 4 weeks before the first administration of Sym004 at Week 1: ... tyrosine kinase inhibitors",
"criterion": "tyrosine kinase inhibitors",
"requirement": {
"requirement_type": "time since last administration",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 4,
"unit": "weeks"
}
]
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "Received any of the following medications within 4 weeks before the first administration of Sym004 at Week 1: ... any investigational agent",
"criterion": "investigational agent",
"requirement": {
"requirement_type": "time since last administration",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 4,
"unit": "weeks"
}
]
}
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Received vaccine therapy as anticancer treatment within 12 weeks before the first administration of Sym004 at Week 1",
"criterions": [
{
"exact_snippets": "Received vaccine therapy as anticancer treatment within 12 weeks before the first administration of Sym004",
"criterion": "vaccine therapy as anticancer treatment",
"requirement": {
"requirement_type": "time since last administration",
"expected_value": {
"operator": "<=",
"value": 12,
"unit": "weeks"
}
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Received vaccine therapy as anticancer treatment within 12 weeks before the first administration of Sym004",
"criterion": "vaccine therapy as anticancer treatment",
"requirement": {
"requirement_type": "time since last administration",
"expected_value": {
"operator": "<=",
"value": 12,
"unit": "weeks"
}
}
}
}
},
{
"identified_line": {
"line": "* Diarrhea of greater than Grade 1 according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 (v4.03)",
"criterions": [
{
"exact_snippets": "Diarrhea of greater than Grade 1 according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 (v4.03)",
"criterion": "diarrhea",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": ">",
"value": 1,
"unit": "Grade"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Diarrhea of greater than Grade 1 according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 (v4.03)",
"criterion": "diarrhea",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": ">",
"value": 1,
"unit": "Grade"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Skin manifestation of greater than Grade 1 according to NCI-CTCAE (v4.03)",
"criterions": [
{
"exact_snippets": "Skin manifestation of greater than Grade 1 according to NCI-CTCAE (v4.03)",
"criterion": "skin manifestation",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": ">",
"value": 1,
"unit": "Grade (NCI-CTCAE v4.03)"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Skin manifestation of greater than Grade 1 according to NCI-CTCAE (v4.03)",
"criterion": "skin manifestation",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": ">",
"value": 1,
"unit": "Grade (NCI-CTCAE v4.03)"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Magnesium of less than 0.9 milligram per deciliter (mg/dL)",
"criterions": [
{
"exact_snippets": "Magnesium of less than 0.9 milligram per deciliter (mg/dL)",
"criterion": "magnesium level",
"requirement": {
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 0.9,
"unit": "mg/dL"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Magnesium of less than 0.9 milligram per deciliter (mg/dL)",
"criterion": "magnesium level",
"requirement": {
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 0.9,
"unit": "mg/dL"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Abnormal organ or bone marrow function as defined in the protocol",
"criterions": [
{
"exact_snippets": "Abnormal organ or bone marrow function",
"criterion": "organ function",
"requirement": {
"requirement_type": "functionality",
"expected_value": "abnormal"
}
},
{
"exact_snippets": "Abnormal organ or bone marrow function",
"criterion": "bone marrow function",
"requirement": {
"requirement_type": "functionality",
"expected_value": "abnormal"
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Abnormal organ or bone marrow function",
"criterion": "organ function",
"requirement": {
"requirement_type": "functionality",
"expected_value": "abnormal"
}
},
{
"exact_snippets": "Abnormal organ or bone marrow function",
"criterion": "bone marrow function",
"requirement": {
"requirement_type": "functionality",
"expected_value": "abnormal"
}
}
]
}
},
{
"identified_line": {
"line": "* Received immunosuppressive agents (including systemic corticosteroids used at doses above 20 milligram per day (mg/day) of prednisolone or equivalent) within 4 weeks before the first administration of Sym004 at Week 1",
"criterions": [
{
"exact_snippets": "Received immunosuppressive agents",
"criterion": "immunosuppressive agents",
"requirement": {
"requirement_type": "receipt",
"expected_value": true
}
},
{
"exact_snippets": "systemic corticosteroids used at doses above 20 milligram per day (mg/day) of prednisolone or equivalent",
"criterion": "systemic corticosteroids",
"requirement": {
"requirement_type": "dose",
"expected_value": {
"operator": ">",
"value": 20,
"unit": "mg/day"
}
}
},
{
"exact_snippets": "within 4 weeks before the first administration of Sym004 at Week 1",
"criterion": "time since last administration",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "weeks"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Received immunosuppressive agents",
"criterion": "immunosuppressive agents",
"requirement": {
"requirement_type": "receipt",
"expected_value": true
}
},
{
"exact_snippets": "within 4 weeks before the first administration of Sym004 at Week 1",
"criterion": "time since last administration",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "weeks"
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "systemic corticosteroids used at doses above 20 milligram per day (mg/day) of prednisolone or equivalent",
"criterion": "systemic corticosteroids",
"requirement": {
"requirement_type": "dose",
"expected_value": {
"operator": ">",
"value": 20,
"unit": "mg/day"
}
}
},
{
"exact_snippets": "within 4 weeks before the first administration of Sym004 at Week 1",
"criterion": "time since last administration",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "weeks"
}
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Active severe infection, any other concurrent disease or medical conditions that are deemed to interfere with the conduct of the trial as judged by the Investigator",
"criterions": [
{
"exact_snippets": "Active severe infection",
"criterion": "infection",
"requirement": {
"requirement_type": "severity",
"expected_value": "severe"
}
},
{
"exact_snippets": "Active severe infection",
"criterion": "infection",
"requirement": {
"requirement_type": "activity",
"expected_value": true
}
},
{
"exact_snippets": "any other concurrent disease or medical conditions",
"criterion": "concurrent disease or medical conditions",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "deemed to interfere with the conduct of the trial as judged by the Investigator",
"criterion": "interference with the conduct of the trial",
"requirement": {
"requirement_type": "judgement",
"expected_value": "Investigator"
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Active severe infection",
"criterion": "infection",
"requirement": {
"requirement_type": "severity",
"expected_value": "severe"
}
},
{
"exact_snippets": "Active severe infection",
"criterion": "infection",
"requirement": {
"requirement_type": "activity",
"expected_value": true
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "any other concurrent disease or medical conditions",
"criterion": "concurrent disease or medical conditions",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "deemed to interfere with the conduct of the trial as judged by the Investigator",
"criterion": "interference with the conduct of the trial",
"requirement": {
"requirement_type": "judgement",
"expected_value": "Investigator"
}
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "* Known human immunodeficiency virus (HIV) positive, active Hepatitis B or C, or uncontrolled allergic conditions or allergy to Sym004 or its components",
"criterions": [
{
"exact_snippets": "Known human immunodeficiency virus (HIV) positive",
"criterion": "HIV status",
"requirement": {
"requirement_type": "presence",
"expected_value": "positive"
}
},
{
"exact_snippets": "active Hepatitis B or C",
"criterion": "Hepatitis B or C status",
"requirement": {
"requirement_type": "activity",
"expected_value": "active"
}
},
{
"exact_snippets": "uncontrolled allergic conditions",
"criterion": "allergic conditions",
"requirement": {
"requirement_type": "control",
"expected_value": "uncontrolled"
}
},
{
"exact_snippets": "allergy to Sym004 or its components",
"criterion": "allergy to Sym004 or its components",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Known human immunodeficiency virus (HIV) positive",
"criterion": "HIV status",
"requirement": {
"requirement_type": "presence",
"expected_value": "positive"
}
},
{
"exact_snippets": "active Hepatitis B or C",
"criterion": "Hepatitis B or C status",
"requirement": {
"requirement_type": "activity",
"expected_value": "active"
}
},
{
"or_criteria": [
{
"exact_snippets": "uncontrolled allergic conditions",
"criterion": "allergic conditions",
"requirement": {
"requirement_type": "control",
"expected_value": "uncontrolled"
}
},
{
"exact_snippets": "allergy to Sym004 or its components",
"criterion": "allergy to Sym004 or its components",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Clinically significant cardiac disease or concurrent, uncontrolled medical condition",
"criterions": [
{
"exact_snippets": "Clinically significant cardiac disease",
"criterion": "cardiac disease",
"requirement": {
"requirement_type": "significance",
"expected_value": "clinically significant"
}
},
{
"exact_snippets": "concurrent, uncontrolled medical condition",
"criterion": "medical condition",
"requirement": {
"requirement_type": "control",
"expected_value": "uncontrolled"
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Clinically significant cardiac disease",
"criterion": "cardiac disease",
"requirement": {
"requirement_type": "significance",
"expected_value": "clinically significant"
}
},
{
"exact_snippets": "concurrent, uncontrolled medical condition",
"criterion": "medical condition",
"requirement": {
"requirement_type": "control",
"expected_value": "uncontrolled"
}
}
]
}
},
{
"identified_line": {
"line": "* Known previous Grade 3 to 4 infusion-related reactions, according to NCI-CTCAE (v4.03), with chimeric monoclonal antibodies",
"criterions": [
{
"exact_snippets": "Known previous Grade 3 to 4 infusion-related reactions, according to NCI-CTCAE (v4.03), with chimeric monoclonal antibodies",
"criterion": "infusion-related reactions",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 3,
"unit": "Grade"
},
{
"operator": "<=",
"value": 4,
"unit": "Grade"
}
]
}
}
},
{
"exact_snippets": "Known previous Grade 3 to 4 infusion-related reactions, according to NCI-CTCAE (v4.03), with chimeric monoclonal antibodies",
"criterion": "infusion-related reactions",
"requirement": {
"requirement_type": "association",
"expected_value": "chimeric monoclonal antibodies"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Known previous Grade 3 to 4 infusion-related reactions, according to NCI-CTCAE (v4.03), with chimeric monoclonal antibodies",
"criterion": "infusion-related reactions",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 3,
"unit": "Grade"
},
{
"operator": "<=",
"value": 4,
"unit": "Grade"
}
]
}
}
},
{
"exact_snippets": "Known previous Grade 3 to 4 infusion-related reactions, according to NCI-CTCAE (v4.03), with chimeric monoclonal antibodies",
"criterion": "infusion-related reactions",
"requirement": {
"requirement_type": "association",
"expected_value": "chimeric monoclonal antibodies"
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Other protocol defined exclusion criteria could apply",
"criterions": [
{
"exact_snippets": "Other protocol defined exclusion criteria",
"criterion": "protocol defined exclusion criteria",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Other protocol defined exclusion criteria",
"criterion": "protocol defined exclusion criteria",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"identified_line": {
"line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "value",
"expected_value": [
"0",
"1"
]
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "value",
"expected_value": "0"
}
},
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "value",
"expected_value": "1"
}
}
]
}
}
],
"failed_exclusion": [],
"failed_miscellaneous": []
}